At NewYork-Presbyterian, we’re advancing cell and gene therapies that harness your body’s own biology to treat cancer, neurodegenerative disease, and rare conditions. Backed by a multidisciplinary team with deep experience in BMT, CAR T, TIL, and gene therapy, we offer leading-edge treatments through clinical trials and standard care. With dedicated support guiding you from insurance eligibility to post-treatment care, and our ongoing innovation in regenerative medicine, we continue to expand what’s possible for patients.
Precision therapies, personalized care
Pioneering new therapies in regenerative medicine
Leading-edge treatments for cancer and more than 20 rare diseases
Dedicated team of coordinators, social workers, and insurance specialists to guide you at every step
Featured areas of care
Cell Therapy Program
Cell therapy uses your own cells to treat disease and restore function, advancing care for cancers, autoimmune, and regenerative conditions with personalized treatment delivered by expert teams across our centers.
Gene Therapy Program
Gene therapy targets genetic disease at its source, correcting or replacing faulty genes to expand what’s possible for a wide range of conditions, with personalized care guided by more than a decade of leading research and experience.
Navigating care and coverage with confidence
Our experts have guided hundreds of patients – across all major insurance plans and from across the country – through the process of accessing advanced therapies. Our team is experienced in navigating complex approvals, including Specialty Care Agreements and Centers of Excellence designations, with established pathways to secure coverage for high-cost care. Every step is coordinated to reduce delays and help you move forward with clarity.
Common conditions treated
- Beta thalassemia
- Bladder cancer
- Blood cancer
- Duchenne muscular dystrophy (DMD)
- Full thickness cartilage defects
- Gastroenteropancreatic Cancer
- Hemophilia A
- Hemophilia B
- Leukemia
- Lou Gehrig's disease (ALS)
- Lung cancer
- Lymphoma
- MacTel Type 2
- Melanoma
- Metachromatic leukodystrophy (MLD)
- Multiple myeloma
- Prostate cancer
- Recessive dystrophic epidermolysis bullosa (RDEB)
- Recurrent respiratory papillomatosis
- Sickle cell disease
- Spinal muscular atrophy (SMA)
- SR-aGVHD
- Wet AMD
- Wiskott-Aldrich syndrome
Clinical trials for advanced care
Our researchers are committed to advancing cell therapies by enhancing their effectiveness, reducing side effects, and expanding reach to more cancers. With onsite capabilities to develop new treatments, we lead clinical trials that bring the latest innovations to patients.
Clinical trials at Weill Cornell Medicine
Clinical trials at Columbia University
Patient spotlight
Jonathan finds hope in a breakthrough sickle cell therapy
Jonathan Lubin’s life was spent in and out of hospitals because of his sickle cell disease. But a new gene-editing therapy offered him the possibility of a life without pain crises.
Advanced therapy news & stories
